Ascendis Pharma A/S (ASND)
225.82
-4.88
(-2.12%)
USD |
NASDAQ |
Sep 25, 16:00
225.82
0.00 (0.00%)
After-Hours: 19:59
Ascendis Pharma Research and Development Expense (Annual) : 333.10M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 333.10M |
| December 31, 2024 | 324.02M |
| December 31, 2023 | 435.86M |
| December 31, 2022 | 387.53M |
| December 31, 2021 | 337.77M |
| December 31, 2020 | 289.09M |
| December 31, 2019 | 208.56M |
| Date | Value |
|---|---|
| December 31, 2018 | 164.52M |
| December 31, 2017 | 111.54M |
| December 31, 2016 | 72.32M |
| December 31, 2015 | 44.33M |
| December 31, 2014 | 25.47M |
| December 31, 2013 | 16.88M |
| December 31, 2012 | 14.08M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Novo Nordisk A/S | 6.838B |
| Evaxion AS | 9.691M |
| Genmab A/S | 1.564B |
| Zealand Pharma A/S | 239.48M |